A Multi-Center Randomized Clinical Trial Correlating the Effects of 24 Months of Exemestane or Letrozole on Surrogate Markers of Response With Aromatase Polymorphism
- Females with at least Stage I-III breast cancer that has not metastasized and it has
been determined it can best be treated with an aromatase inhibitor
- 18 years of age or older
- Both breasts have been surgically removed
- Have previously had radiation therapy to the unaffected breast
- Have previously taken an aromatase inhibitor
- Have a history of cancer of ovarian, endometrial, fallopian tube, and primary
Type of Study:
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Identify which women are more likely to have certain benefits or side effects from one or the other of exemestane and letrozole. The researchers will be looking at their genes and at the medication's effects on their body.
Outcome Time Frame:
refer to protocol
Daniel Hayes, M.D.
University of Michigan
United States: Institutional Review Board
- Breast Cancer
- breast cancer best treated with aromatase inhibitors.
- Breast Neoplasms
|University of Michigan||Ann Arbor, Michigan 48109-0624|